Pareek Manan, Kragholm Kristian H, Kristensen Anna Meta Dyrvig, Vaduganathan Muthiah, Pallisgaard Jannik L, Byrne Christina, Biering-Sørensen Tor, Lee Christina Ji-Young, Bonde Anders Nissen, Mortensen Martin Bødtker, Maeng Michael, Fosbøl Emil L, Køber Lars, Olsen Niels Thue, Gislason Gunnar H, Bhatt Deepak L, Torp-Pedersen Christian
Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Gentofte Hospitalsvej 4, 2900 Hellerup, Denmark.
Department of Cardiology, Copenhagen University Hospital - North Zealand Hospital, Dyrehavevej 29, 3400 Hillerød, Denmark.
Eur Heart J. 2023 Feb 7;44(6):502-512. doi: 10.1093/eurheartj/ehac629.
Long-term prognostic implications of serial high-sensitivity troponin concentrations in subjects with suspected acute coronary syndrome are unknown.
Individuals with a first diagnosis of myocardial infarction, unstable angina, observation for suspected myocardial infarction, or chest pain from 2012 through 2019 who underwent two high-sensitivity troponin-T (hsTnT) measurements 1-7 h apart were identified through Danish national registries. Absolute and relative risks for death at days 0-30 and 31-365, stratified for whether subjects had normal or elevated hsTnT concentrations, and whether these concentrations changed by <20%, > 20 to 50%, or >50% in either direction from first to second measurement, were calculated through multivariable logistic regression with average treatment effect modeling. Of the 28 902 individuals included, 2.8% had died at 30 days, whereas 4.9% of those who had survived the first 30 days died between days 31-365. The standardized risk of death was highest among subjects with two elevated hsTnT concentrations (0-30 days: 4.3%, 31-365 days: 7.2%). In this group, mortality was significantly higher in those with a > 20 to 50% or >50% rise from first to second measurement, though only at 30 days. The risk of death was very low in subjects with two normal hsTnT concentrations (0-30 days: 0.1%, 31-365 days: 0.9%) and did not depend on relative or absolute changes between measurements.
Individuals with suspected acute coronary syndrome and two consecutively elevated hsTnT concentrations consistently had the highest risk of death. Mortality was very low in subjects with two normal hsTnT concentrations, irrespective of changes between measurements.
疑似急性冠状动脉综合征患者连续高敏肌钙蛋白浓度的长期预后影响尚不清楚。
通过丹麦国家登记处识别出2012年至2019年首次诊断为心肌梗死、不稳定型心绞痛、疑似心肌梗死观察期或胸痛且间隔1 - 7小时进行两次高敏肌钙蛋白T(hsTnT)测量的个体。通过多变量逻辑回归和平均治疗效果模型计算第0 - 30天和第31 - 365天死亡的绝对风险和相对风险,根据受试者hsTnT浓度正常或升高以及这些浓度从首次测量到第二次测量在任一方向上变化<20%、>20%至50%或>50%进行分层。在纳入的28902名个体中,2.8%在30天时死亡,而在前30天存活的个体中有4.9%在第31 - 365天之间死亡。hsTnT浓度两次升高的受试者标准化死亡风险最高(0 - 30天:4.3%,31 - 365天:7.2%)。在该组中,从首次测量到第二次测量升高>20%至50%或>50%的个体死亡率显著更高,不过仅在30天时如此。hsTnT浓度两次正常的受试者死亡风险非常低(0 - 30天:0.1%,31 - 365天:0.9%),且不取决于测量之间的相对或绝对变化。
疑似急性冠状动脉综合征且hsTnT浓度连续两次升高的个体死亡风险始终最高。hsTnT浓度两次正常的受试者死亡率非常低,与测量之间的变化无关。